<DOC>
	<DOC>NCT01467401</DOC>
	<brief_summary>This trial is conducted in Europe. The aim of this trial is to investigate the efficacy and safety of biphasic insulin aspart (NovoMix®30) to that of biphasic human insulin (Mixtard® 30) in subjects with type 2 diabetes.</brief_summary>
	<brief_title>Efficacy and Safety of NovoMix® 30 in Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin aspart, insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<criteria>Type 2 diabetes for at least 24 months Insulin treatment for the pase 3 months HbA1c (glycosylated haemoglobin) below 13% BMI (Body Mass Index) below 40 kg/m^2 Ability and willingness to perform selfblood glucose monitoring Receipt of any investigational drug within 4 weeks prior to this trial Treatment of OHAs (Oral Hypoglycaemic Agents) within 4 weeks prior to this trial Total daily insulin dosage less than or equal to 1.8 IU/kg</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>